Roche India and Cipla announce launch of Roche’s Antibody Cocktail in India. Roche’s Antibody Cocktail will use for the treatment of mild to moderate COVID-19 in patients who are at high risk.
This Antibody Cocktail is to be use for the treatment of mild to moderate COVID-19 in adults and pediatric patients who are confirmed to be infected with SARS-COV2 and are at high risk of developing severe COVID-19 disease and do not require oxygen.
Price in India
Roche’s Antibody Cocktail in India price set at Rs 59,750 per dose.
The price for each patient dose which is a combined dose of 1,200 mg (600 mg of Casirivimab and 600 mg of Imdevimab)] will be Rs 59,750 inclusive of all taxes.
The maximum retail price for the multi dose pack by which each pack can treat two patients is Rs 1,19,500 inclusive of all taxes.
The drug will be available through leading hospitals and COVID treatment centers.
The Central Drugs Standards Control Organisation (CDSCO) had recently provided an emergency use authorisation (EUA) for the Antibody Cocktail (Casirivimab and Imdevimab) in India.
Antibody Cocktail has also received a EUA in the US and several EU countries.
Cipla and Roche Said :
“The first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in India offers treatment for two patients,”.
Cipla will distribute the product by leveraging its strong distribution strengths across the country.
V Simpson Emmanuel, Managing Director and CEO, Roche Pharma India Said :
“We are optimistic that the availability of Antibody Cocktail (Casirivimab and Imdevimab) in India can help in minimising hospitalisation, ease the burden on healthcare systems and play a key role in treatment of high risk patients before their condition worsens,”.
Umang Vohra, MD and Global CEO Cipla Said :
“We look forward to leveraging our solid marketing and distribution strengths in India to provide broader, equitable access to this innovative treatment option in the country.”
